Zymeworks Inc. announced on August 11, 2025, the appointments of Greg Ciongoli and Robert E. Landry to its Board of Directors, effective August 10, 2025. Both individuals were also appointed as members of the audit committee of the Board, enhancing financial oversight and strategic guidance.
Mr. Ciongoli, Founder and Managing Partner of Adiumentum Capital Management, brings over 16 years of experience from The Baupost Group, where he led investments in public and private companies across various industries, with a focus on healthcare investments and corporate governance. Mr. Landry offers more than 30 years of global financial leadership experience from the pharmaceutical and biotechnology sectors, including roles as Chief Financial Officer at Regeneron Pharmaceuticals Inc. and senior financial leadership at Wyeth and Pfizer, Inc.
Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, stated that their extensive financial and strategic leadership expertise will be invaluable as the company advances its development programs and executes its long-term growth strategy. This move is expected to support Zymeworks during a significant period of opportunity, including upcoming data readouts and continued pipeline progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.